Linaclotide A Success for CIC and IBS-C Therapy

Linaclotide A Success for CIC and IBS-C Therapy


Fourth quarter results from Ironwood Pharmaceuticals, marketers of Linzess, or Linaclotide, were glowing. Net sales in the United States of Linzess were estimated at $93.8 million for the fourth quarter of 2014, which was a sizable 18 percent quarter over quarter increase. This exciting news was shared in mid-February 2015, with financial gains for Linaclotide proving to be more profitable than planned. Over 440,000 prescriptions were filled in the fourth quarter of 2014 for Linzess (Linaclotide) which was an increase of 12 percent quarter over quarter. A staggering 2 million prescriptions for Linzess have been filled since its debut in December of 2012. These figures remain upbeat for this formidable therapy, designed for treating patients with both chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

As the only and the first guanylate cyclase-C agonist approved by the FDA, Linaclotide has proven to be a viable treatment for acting locally in the intestine to speed gastrointestinal transit and for reducing gastrointestinal pain and discomfort.

Offered in oral capsules, the approved dosage of Linaclotide is as follows:

  • IBS-C– 290 mcg one time daily, preferably on an empty stomach. Ideal administration should be at least 30 minutes before the first meal of the day.
  • CIC– 145 mcg daily, preferably 30 minutes before the first meal of the day.

Linaclotide is contraindicated for use in children ages six and younger. The safety and efficacy has been established for patients ages 18 and older for when using Linaclotide. Serious adverse effects from Linaclotide are uncommon, with most common side effects reported being diarrhea, flatulence and abdominal discomfort.

Chronic idiopathic constipation effects almost 30 million Americans, with between 12 and 19 percent of Americans having fewer than three bowel movements a week, which are difficult to pass. Linaclotide achieved study goals in patients with CIC, and also helped reduce bloating, abdominal pain and the severity of constipation in patients. Approximately 62 percent of patients who received Linaclotide in studies expressed that they were “very likely” to continue using this therapy after the study concluded.

Linaclotide is also effectual for treating patients with irritable bowel syndrome with constipation. By increasing the secretion of chloride and water in the intestines Linaclotide not only softens stools but it also stimulates bowel movements.

LGM Pharma can assist clients as a supplier/distributor of the API Linaclotide, CAS # 851199-59-2, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service